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The actin cytoskeleton is a dynamic structure which is capable of rapid assembly and 
disassembly, and has roles in the structural stability and migration of the cell. Cofilin 1 
(Cof1) is an intracellular protein which depolymerises F-actin whilst inhibiting the 
polymerisation of G-actin, and as such dissembling the actin cytoskeleton, in a pH 
dependant way. Cofilin 1 has also been linked to the function and regulation of 
mitochondria in Saccharomyces cerevisiae. Mutations in the COF1 gene have been 
connected to drug resistance to numerous antifungals in Saccharomyces cerevisiae. One 
such mutant is the cof1-6 strain whose mutations are present outside of the charge - 
dependant PtdIns(4,5)P2 binding site of Cofilin 1, and has been linked to the up-regulation 
of several ABC transporters that have roles in drug resistance. We investigate the role of 
genes involved in lipid biosynthesis and the role of the mitochondrial outer membrane 
protein Porin 1 in cof1-6 linked drug resistance. We show that the Cof1-6 mediated drug 
resistance is PKC-regulated MAPK pathway independent. We further observe an increase 
in the expression of the sphingoid long chain base efflux pump Rsb1 in the cof1-6 strain. 
This up-regulation of Rsb1 is pH-independent but Porin dependent.  Previous literature has 
demonstrated a link between peroxisomal and mitochondrial function. Our work suggests 
that peroxisome function does not regulate drug resistance whereas mitochondrial 
function is a key mediator in the resistance phenotype of the cof1-6 strain. Furthermore, 
we demonstrate that cof1-6 linked drug resistance is very complex with the ABC 
transporter Pdr5 involved in resistance to antifungals which operate through different 
modes of action. We hope that this work will further understanding into drug resistance 

















1. Drug Resistance 
Drug resistance is a phenomenon that occurs when microorganisms or cancer cells have 
evolved in such a way that medications they used to be sensitive to are no longer 
effective. This presents a problem when pathogenic organisms gain resistance to drugs 
that are used to treat them, even more so when those resistant pathogens spread 
amongst a population. Drug resistance can develop due to spontaneous mutations but 
can also occur due to the wrong treatments being prescribed or prescribed courses of 
treatments not being completed. An estimated one million deaths per year occur due 
to fungal infections, mostly in immune-compromised individuals. 
 
1.1 The ABC Transporter Superfamily 
ATP-binding cassette transporters, or ABC transporters as they are more commonly known, 
are members of one of the largest superfamilies of proteins. These proteins are conserved 
in a range of organisms from single-celled to multi-celled organisms and are broken up into 
7 different subfamilies. These subgroups are referred to as, ABCA, ABCB, ABCD, ABCE, 
ABCF, and ABCG (Prasad, Khandelwal, and Banerjee 2016). The classes of ABC transporters 
are dependent on the number ŽĨɲ-helices that span the cell membrane, usually varying 
between 6 and 10 (Wilkens, 2015). ABC transporters commonly comprise multiple domains 
, at least one of which is a transmembrane subunit, and another is an ATP binding subunit, 
giving the name to the family (Jungwirth & Kuchler, 2006). Again, as their name indicates, 
they are involved in the transport of substrates across various cell membranes.  
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They can also be divided into different groups based on their function in eukaryotes, 
prokaryotes, or both. These groups are importers, exporters, and a third group that are not 
involved in transportation directly which have roles in the repair of DNA and translation  
(Davidson et al, 2008). Importers can be broken in to two further groups depending on their 
mechanism and structure. Importers are found in bacteria whilst eukaryotes, on the most 
part, only feature exporters (Davidson et al, 2008). Functionally, most ABC transporters 
pump substrate against the gradient, and as such, require ATP to work, and almost all only 
work in one direction (Vasiliou et al, 2009). As such, the transmembrane domains act like 
gates and change conformation (Wilkens, 2015).  
 
1.2 Structure of ABC transporters 
Structurally, ABC transporters have two nucleotide binding domains (NBDs), named NBD1 
and NBD2, and two transmembrane domains (TMDs) named TMD1 and TMD2 (Wilkens, 
2015). Whilst bacteria have ABC transporters with subunits made up of individual 
polypeptide chains, eukaryote ABC transporters usually have one polypeptide which 
contains all the transmembrane and nucleotide binding domains (Wilkens, 2015). The NBD 
region of the transporters is highly conserved as it contains the ATP binding region, a 
hallmark of the ABC transporters (Jungwirth & Kuchler, 2006). As such the NBD region is 
conserved throughout almost all ABC transporters in bacterial, fungal and mammalian cells, 
and is a feature which allows ABCs to be identified (Biemans-Oldehinkel et al, 2006). 
Between bacterial and eukaryotic cells, similarity between sequences can be as high as 30-
50%, with the 3-fold structure and energy coupling mechanism being conserved (Sharma 





1.3 ABC transporters in lipid transport 
A major role of ABC transporters in cells is the movement of lipids and their precursors 
(Prasad, Khandelwal, and Banerjee 2016). Lipid transport is essential and defects found in 
its mechanism can cause cell dysfunction and lead to disease (Prasad, Khandelwal, and 
Banerjee 2016). Within mouse systems the ABC transporter Mdr1 has the ability to move 
fluorescent lipid analogues between the leaflets of the cell membrane, whereas Mdr2 is 
involved in the movement of certain phospholipids into bile (Zhou et al, 1999; Oude Elferink 
et al, 1995). Within human systems Mdr1 has a very similar role to Mdr1 found in mice. 
These MDR (multidrug resistance) genes have links to multidrug resistance in tumour cells 
(Wang et al, 2017, 2015).  Vaidyanathan et al. showed that MDR1 P-glycoprotein levels 
correlated with resistance to paclitaxel and olaparib in resistant ovarian cancer cells, and 
Figure 1.1 A simple schematic diagram of an ABC transporter. The top image is a simple depiction of how the ABC 
transporter functions, whilst the bottom image shows the ɲ-helices spanning the cell membrane (Rees et al, 2009). 
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when treated with a P-glycoprotein inhibitor, the resistance was reversible (Vaidyanathan 
et al, 2016).  
Yeast cells utilise a similiar system of ABC transporters to import and export lipids. In 
Saccharomyces cerevisiae, Pdr5 is a phospholipid transporter, whilst Pdr11 imports sterols 
across the lipid membrane (Schulz & Prinz, 2007). These PDR (pleiotropic drug resistance) 
ABC transporters are linked to their MDR counterparts in mammalian cells, and are also 
seen to convey drug resistance to the cell (Jungwirth & Kuchler, 2006). This drug resistance 
phenotype is often a result of overexpression of the PDR transcription factors that in turn 
result in the overexpression of these efflux pumps (Mahé et al, 1996). In S. cerevisiae, the 
main transcription factors responsible are Pdr1 and Pdr3, which in turn can activate Pdr5p 
as well as other ABC transporters involved in resistance such as Snq2p, which also has roles 
in quorum sensing, and Yor1p, responsible for oligomycin resistance  ?,ůĂǀĄēĞŬet al, 2009; 
Katzmann et al, 1995). These zinc finger transcription factors bind to Pdr1/Pdr3 Response 
Elements (PDREs) on the promotor regions of target genes in order to express them (Shahi 
& Moye-Rowley, 2009).  The Pdr1 and Pdr3 transcription factors also upregulate proteins 
not related to drug resistance, such as Rsb1, a sphingoid long chain base transporter in the 
case of PDR1, and proteins that are involved in DNA damage repair in the case of PDR3 
(Ikeda et al, 2008; Katzmann et al, 1994).  
 
1.4 The yeast cell wall 
The Saccharomyces cerevisiae cell wall is a structure that surrounds the cell and is around 
70-100nm thick (Klis et al, 2002). The cell wall fulfils many essential functions within a yeast 
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cell, namely providing protection against physical stress, maintaining osmotic conditions 
within the cell, maintaining the shape of the cell and acting as a supporting structure for 
cellular proteins (Orlean, 2012; Kollár et al, 1997). In Saccharomyces cerevisiae, the shape 
of the cell wall is crucial for forming the bud, and subsequently cell division (Cabib et al, 
2001; Lesage & Bussey, 2006). As such, the cell wall structure is highly regulated, with 
specific proteins and lipids which differentiate depending on the extracellular and 
intracellular conditions, which thickness increasing in the presence of varying pH, 
temperature, and oxygen levels in vivo, as well as the composition of the growth media in 
vitro (Aguilar-Uscanga & François, 2003).  
Other factors that can affect the composition of the cell wall are the stage of growth in 
which the cell is in, mutations in genes responsible for wall formation and drug treatment 
(Lesage & Bussey, 2006; Dijkgraaf et al, 2002; Dallies et al, 1998). The cell wall of S. 
cerevisiae can make up almost 25% of the cells dry mass with around 1200 different genes 
having an involvement, of this, around 50-60% of the dry mass is due to the inner layer of 
the wall (Klis et al, 2002; de Groot et al, 2001). Cells in the logarithmic phase are more 
porous with soluble glycoproteins of up to 400kDa being able to pass through the growing 
cell wall. One of the properties of the cell wall is its hydrophobic ability due to the numerous 
phosphodiester bridges that the surface proteins contain that allow the cell wall to be 
hydrophobic at the pH range found inside the body. 
Broadly, the components of the fungal cell wall can be split into 3 groups. The first is chitin 
or chitosan, the second is glucan and the third is a huge array of proteins which can be 
specific to individual yeasts or shared amongst the whole family (Kollár et al, 1997). Chitin 
is synthesized in the plasma membrane of the cell and is either made up of polymers of N-
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AcetyůŐƵĐŽƐĂŵŝŶĞůŝŶŬĞĚŝŶĂɴ ?-4 structure (Lenardon et al, 2010). Glucans can be either 
ɲŽƌɴůŝŶŬĞĚǁŝƚŚɴŐůƵĐĂŶƐĂĚĚŝŶŐƌŝŐŝĚŝƚǇƚŽƚŚĞĨƵŶŐĂůĐĞůůǁĂůů ?ĂƐǁĞůůĂƐŵĂŬŝŶŐƵƉƚŚĞ
ŵĂũŽƌƐĐĂĨĨŽůĚ ?ǁŚŝůƐƚɲŐůƵĐĂŶƐĂĐƚĂƐƉĂƌƚŽĨƚŚĞĐĞůůŵĂƚƌŝǆ (Synytsya & Novak, 2014). The 
1- ?ɴ-glucan molecules bind through hydrogen bonds which results in a highly elasticated 
and flexible structure (Miyoshi et al, 2004). The wall is split into an inner and outer section, 
ǁŝƚŚƚŚĞŝŶŶĞƌƐĞĐƚŝŽŶďĞŝŶŐĐŽŵƉŽƐĞĚŵŽƐƚůǇŽĨɴ ? ?-glucan and chitin, whereas the outer 
wall is comprised mostly of mannoproteins which are highly glycosylated, limiting the walls 
exposure to degrading enzymes (Klis et al, 2002).   
The proteins present in the cell wall often contain mannose, and are responsible for adding 
rigidity as well as synthesis of the cell wall (Kollár et al, 1997). Proteins that are attached to 
the cell wall can be further broken down into 3 subgroups based on their function within 
the cell (Orlean, 2012). The first and second group contain glycosylated proteins, with the 
first comprising of proteins that can aid in the building of the wall such as hydrolases, and 
the second being proteins which bind the cell wall components together like agglutinins 
 ?dĞƉĂƌŝđ  ? DƌƓĂ ?  ? ? ? ? ). The third and final group are proteins which pass through the 
membrane once and have serine and threonine rich extracellular regions as well as short 
intracellular domains (Lesage & Bussey, 2006; Gentzsch & Tanner, 1997). Members of the 
third group of associated proteins include proteins that act as sensors of cell stress such as 
Mtl1 which monitors oxidative stress during glucose starvation (Klis et al, 2006). 
One of the major components of the lipid bilayer is sphingomyelin which is made up of 
ceramide components, whose synthesis is discussed below. Ceramide has a role in 




1.5 Responses to cell wall Stress 
MAPK signalling regulates a varying amount of processes within the cell, ranging from 
proliferation and apoptosis to gene expression (Levin, 2005). The MAPK pathway that is 
involved in the regulation of the cell wall stability and most studied is the Cell Wall Integrity 
(CWI) pathway, activated by PKC (Levin, 2005) . As well as regulating the cells response to 
cell wall stress such as cell wall damage by antifungal agents, this pathway regulates mating 
and response to high osmolality amongst other roles. In a linear kinase cascade, Pkc1 firstly 
phosphorylates Bck1 at several sites between its catalytic and regulatory domains, namely 
Ser939, Thr1119 and Ser1134, activating it (Levin et al, 1994). Bck1 goes on to 
phosphorylate Mkk1/2 which subsequently goes on to activate Slt2 (Irie et al, 1993). This 
cascade allows small signals on the cell surface to be amplified as long as the threshold of 
the cell surface receptor is reached. Both Mkk1/2 and Slt2 both reside in the cytoplasm 
during a stress response, whereas Pkc1 is localised at the cell membrane (Kamada et al, 
1995). In response to a cell wall stress detected by Rho1 and Rho2 GTPases on the cell 
surface, this pathway is activated (Santos et al, 2003). When Slt2 is phosphorylated, it goes 
on the activate Plm1 and Swi4 which are transcription factors that upregulate genes 
involved in cell wall synthesis, including GSC2 which codes for ɴ ? ? ?-glucan synthase, which 
in turn is involved in the formation of ɴ ? ? ?-glucan (Douglas et al, 1994). 
 
1.6 The cell wall as a target of antifungal drugs 
Due to its important function in the maintenance and survival of the cell, the cell wall is an 
attractive therapeutic target against pathogenic fungi, targeting different components of 
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the wall, and its synthesis. The main target for a lot of azole drugs is the cytochrome P450 
ůĂŶŽƐƚĞƌŽů  ? ?ɲ-demethylase which is a component in the pathway responsible for 
ergosterol synthesis (Yoshida, 1988). These drugs are successful in reducing the amount of 
ergosterol in the lipid membrane which makes the membrane weaker and more prone to 
antifungal drug action. Ergosterol is produced by removing two of the methyl groups from 
lanosterol and thus ergosterol is a smaller molecule that its predecessor (Nes, 2011) ? ? ?ɲ-
demethylase is the enzyme responsible for this step and drugs like itraconazole and 
clotrimazole inhibit this enzyme preventing ergosterol formation (De Backer et al, 2001). A 
reduction of ergosterol results in the increased permeability of  the cell wall, resulting in 
magnesium potassium diffusing out of the cell (Ellis, 2002). Azole drugs indirectly target the 
cell wall, and are usually thought to be fungistatic because they limit ability to make 
membrane and/or produce toxic sterol intermediates. An example of these toxic 
intermediates are  ? ?ɲ-methylated sterols which result in an increase in the fluidity of the 
membrane and increased permeability to other drugs (Sorgo et al, 2011; Abe et al, 2009). 
However lack of ergosterol synthesis will also affect cell wall building/assembly as it is an 
essential component of the cell wall (Lesage & Bussey, 2006). 
Other drugs like Amphotericin B, a member of the polyene class of drugs, binds to the 
ergosterol directly, forming pores in the membrane which lead to the leakage of 
monovalent ions such as potassium, sodium and chloride ions (Mesa-Arango et al, 2012). 
Unlike the azole class of drugs however, Amphotericin B is not fungal specific and will bind 
to other members of the sterol class of molecules including cholesterol, found in 
mammalian cells (Paquet et al, 2002). As a result of this non specificity, Amphotericin B is 
toxic in humans and results in nephrotoxicity, fever and chills, as well as nausea and 







1.7 Role of lipids in Saccharomyces cerevisiae 
Lipids have many important roles in the function of the cell and are integral as a source of 
both structure and energy within cells. They are a major component of cell membranes but 
also act with signalling pathways as both primary and secondary messengers (Nakamura et 
al, 1995; Ohanian et al, 1998). Lipids such as diacylglycerol act as secondary messengers 
which are associated to the cell membrane and can diffuse into the cell in response to 
primary messengers. Due to their hydrophilic properties, lipids easily form structures such 
as vesicles, liposomes and cell membranes both intracellularly and extracellularly. 
Figure 1.2 De nova production of ergosterol in S. cerevisiae and potential drug targets. This is the mechanism by 




Examples of lipids important to the cell membrane structure in Saccharomyces cerevisiae 
are ergosterol and sphingolipids.  
 
1.7.1 Ergosterol Biosynthesis in Saccharomyces cerevisiae 
Ergosterol is a member of the subgroup of steroids known as sterol alcohols or sterols. It 
has many similar properties and functions as cholesterol does is mammalian cells, although 
ergosterol requires more energy expenditure to produce (Nes, 2011; Slominski et al, 2005). 
Ergosterol in a major component in the fungal lipid membrane. It is fungal equivalent to 
cholesterol in humans and a target for the group of antifungal agents known as azoles 
(Lupetti et al, 2002). Ergosterol is not universally present in all fungi and in some, such as 
S. cerevisiae, some components in the pathway are not essential to viability like the other 
steps are. It is also not present in mammalian cells and, as such, is a good pharmacological 
target, as the drugs will not cause damage to host cells whilst targeting the pathogenic 
fungi (Ghannoum & Rice, 1999). As such the ergosterol biosynthesis pathway is targeted by 
a lot of antifungal drugs. 
Ergosterol is the final product in a long process which included many intermediates 
(Dupont et al, 2012). A simplified process is shown in, along with associated drug targets, 
in Figure 1.2 and occurs at the rough ER of the cell. From the ER, it needs to be transported 
to the plasma membrane. This can occur either by contact sites between the ER and other 
organelles or through the use of transport proteins called oxysterol-binding protein (OSBP)-








1.7.2 Sphingolipid Biosynthesis in Saccharomyces cerevisiae 
Sphingolipids are lipids which have a similar structure to that of phospholipids in that they 
both are made up of a polar head group and two non-polar tails (Gault et al, 2010). 
However, with the exception of sphingomyelins, these two membrane molecules are 
individual classes. Sphingolipids have a core made of sphingosine which is a long chain 
amino alcohol which contains an eighteen carbon amino alcohol backbone(Gault et al, 
2010). The basic sphingolipid structure undergoes post translational modification in the ER, 
Figure 1.3 Ergosterol transport in S. cerevisiae. This is an overview of the key transport mechanisms that are 
involved in the movement of ergosterol around the cell (Jacquier & Schneiter, 2012). 
23 
 
and then to the Golgi apparatus to produce the vast family of sphingolipids which are found 
in cells. All sphingolipids share a common synthesis and catabolism pathway. 
Sphingolipid metabolism starts with the production of the sphingoid bases which make up 
the backbone of the sphingolipid itself. These are produced through palmitoyl-coenzyme A 
and serine condensing together to form 3-ketosphinganine, through the catalytic action of 
serine palmitoyltransferase (Mandon et al, 1992). This initial reaction occurs in the 
endoplasmic reticulum ?Ɛ cytosolic side. Once 3-ketosphinganine has been produced, it is 
then reduced to sphinganine by the enzyme 3-ketosphinganine reductase (Pinto et al, 
1992). The next step in the process is the acylation of the sphinganine to form 
dihydroceramide through a process involving six ceramide synthase enzymes in mammals, 
and sphinganine N-acyl transferases in yeast, which involves attaching different length fatty 
acid chains (Sugimoto et al, 2004). This dihydroceramide undergoes a process of 
unsaturation by dihydroceramide desaturase 1 to form ceramide which is the direct 
precursor to sphingosine. Sphingosine is formed from ceramide by ceramidase however its 
conversion is reversible by the action of the enzyme ceramide synthase (Gault et al, 2010). 
To convert sphingosine back into ceramide requires the addition of fatty acyl-coA, resulting 
in ceramide and CoA-SH. Ceramide can also be formed by the hydrolysis of sphingomyelin 
by sphingomyelinase, as opposed to the de nova pathway which is as described above. 
The membranes in which certain sphingolipids are found differs based on their size and 
side chains. For example, dihydrosphingosine and sphingosine, normally accumulate in 
organelles which have an acidic pH as their free amino group is open to ionisation, whereas 
ceramide is found more in cell membranes as it flips within membranes rapidly and is 
localised often to membrane where it was synthesised. This property of ceramide is 
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important as an important step in its modifications requires enzymes localised in the 
membrane it was created in (Gault et al, 2010).  
Movement of the newly formed ceramide to the Golgi apparatus is done through the use 
of vesicles or the ceramide transfer protein CERT which is localised in the cytosol and moves 
the ceramide from the ER to the Golgi apparatus where it can then be modified post 
translationally to form either sphingomyelins or glycosphingolipids (Hannun & Obeid, 
2008). The CERTs are directed to the Golgi apparatus through the presence of a pleckstrin 
homology domain of around 120 amino acids on the N-terminus which recognises and 
moves towards the PI4P of the Golgi (Raya et al, 1999). The primary residue found on the 
C1 hydroxy group on the sphingolipids determines their class, and this is determined by 
three distinct pathways that runs through the ER and Golgi apparatus organelles (Gault et 
al, 2010). 
 
 Figure 1.4 De nova production of sphingolipids in S. cerevisiae. This is the mechanism by which sphingolipids, a 
major component of the cell wall, are made in yeast (Kihara & Igarashi, 2002b). 
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Rsb1 is a transporter of the sphingoid bases precursors that make up these sphingolipids 
(Kihara & Igarashi, 2002a). The sphingoid bases also act as signalling molecules, for example 
they can signal though Pkh kinases to induce endocytosis in yeast cells (Friant et al, 2001).  
The regulation of sphingolipids and their precursors has been linked to drug resistance in 
cancer cells. In particular, ceramide accumulation has been seen to be increased in various 
resistant cancers, leading to the overproduction of glucosylceramide (GlcCer) (Gouazé et 
al, 2005). This in turn leads to leads to an increase in GlcCer synthase (GCS) activity and 
expression. GCS has been seen to lead in an increase of expression of Mdr1 which can be 
reduced by using a GCS inhibitor in breast cancer cells (Gouazé et al, 2005). 
 
1.8 Function of Mitochondria and their role in metabolism 
The mitochondria are double membraned organelles that are the site of ATP production 
within almost all eukaryotic cells. They also have a major role in metabolism within the cell, 
including phospholipid synthesis, through the conversion of phosphatidylserine (PS) to 
phosphatidylethanolamine (PE), as well as activation of apoptosis and cell death (Kojima et 
al, 2016; Gulshan et al, 2008). They have also been shown to be involved in steroid 
synthesis and the regulation of the metabolism of the wider cell (McBride, Neuspiel, and 
Wasiak 2006; Rossier 2006). 
There are many diseases which have been linked to mitochondrial function, of which many 
are endocrine diseases such as diabetes mellitus (Larsson et al, 2000). Mitochondria also 
have a separate genome to the cell, and although they still have most of their key proteins 
coded for by the nuclear genome, they are also able to encode a few essential respiratory 
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proteins required for function independently. Mutations in this mitochondria DNA can let 
rise to diseases of its own such as Mitochondrial Encephalomyopathy with Lactic Acidosis 
and Stroke-like episodes (MELAS) and Leigh syndrome (Baertling et al, 2014; El-Hattab et 
al, 2015). 
Mitochondria have been seen to play a key role in apoptosis and mitochondrial damage is 
seen to have an effect on ageing (Wang & Youle, 2009). Caspases are proteases that cleave 
many cellular proteins resulting in cell apoptosis and are key proteins in the apoptosis 
process (Salvesen & Dixit, 1997). Proteases such as Smac and Omi that usually reside within 
the mitochondria, and whose primary role is to perform functions required for cell growth, 
are also activators of caspase activity (Vande Walle et al, 2008).  
Most of the functions of the mitochondria are reliant on the proton gradient generated by 
respiration within the cristae of the mitochondria. This proton gradient is required for ATP 
synthesis as well as the movement of calcium ions and the entry of proteins in the 
mitochondria (Duchen & Szabadkai, 2010).  
The entry and exit of these calcium ions and other small molecules occurs through pores in 
the mitochondrial outer membrane called porins that regulate the membranes 
permeability (Weeber et al, 2002). These porins, also known as voltage-dependant anion 
channels (VDACs), are highly conserved structures made up of beta sheets, forming a beta 
barrel structure (Sampson et al, 1996). Porin 1, the most abundant porin in the 
mitochondrial membrane is formed of 19 of these beta-sheets with both the N- and C-
terminus facing the mitochondrial intermembrane space (Tomasello et al, 2013). As well as 
being the most abundant, porin 1 is also the main calcium ion channel as well as being 
27 
 
responsible for the transport of ATP and other ions across the mitochondrial membrane 
(Tomasello et al, 2013; Chu et al, 2014). 
Cells missing their mitochondrial DNA have been seen to upregulate Pdr5, establishing a 
link between mitochondria and drug resistance (Moye-Rowley, 2005). Moye-Rowley 
hypothesised that the upregulation of Pdr5 could be a compensation mechanism to export 
toxic intermediates that accumulate in the inactive mitochondria but the exact mechanism 
is yet to be determined (Moye-Rowley, 2005). 
 
1.9 Drug resistance in Saccharomyces cerevisiae  
As mentioned previously, multidrug resistance in Saccharomyces cerevisiae resistance is 
linked to overexpression of certain ABC transporters such as Pdr5, as well as Snq2 and Yor1 
(Nourani et al, 1997). Pdr5 is a member of the ABCG subclass of transporters and in 
knockout studies, the PDR5 gene knockouts resulted in increased sensitivity to an array of 
drugs (Paumi et al, 2009; Gulshan & Moye-Rowley, 2007). 
These proteins have roles in lipid transport but they also are transporters of many 
antifungal agents that are in use today. The two predominant transcription factors for the 
PDR genes are Pdr1 and Pdr3 which bind to PDRE sites on their target gene. The number of 
PDREs on a gene correlates strongly to how sensitive they are to the levels of transcription 
factor in the cell. In the case of PDR5 which is the most abundant PDR gene within S. 
cerevisiae, it has three PDRE sites and so is highly sensitive (Katzmann et al, 1996). As well 
as PDR1 and PDR3, the PSD1 gene which encodes phosphatidylserine decarboxylase has 
been linked to the upregulation of the protein Pdr5 (Clancey et al, 1993).  
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As well as Pdr5 which is specific for itraconazole, amphotericin B and cycloheximide, there 
is other ABC transporters which are specific for other drug substrates (Gulshan & Moye-
Rowley, 2007). Pdr15 is a Pdr5 homologue and is specific to similar classes of drugs, 
whereas Yor1 of the ABCC family, bestows oligomycin resistance on a cell (Katzmann et al, 
1995).  
 
1.10 Drug resistance in Candida albicans   
Drug resistance in pathogenic yeast is an ever-growing problem. Candida albicans is a 
pathogenic yeast which also displays acquired drug resistance, whilst being more resistant 
to metabolic inhibitors than the yeast S. cerevisiae. Candida have their own genes that 
convey resistance such as CDR1, Candida Drug Resistance 1, which is functionally 
equivalent to PDR5 found in S. cerevisiae as discovered by Prasad et al. by transforming 
CDR1 in to a PDR5 knockout. Addition of this CDR1 gene results in drug resistance to 
cycloheximide amongst others (Prasad et al, 1995). Whilst CDR1 is functionally equivalent 
and encodes for a similar ABC transporter, the drugs that it gains resistance to is altered 
(Prasad et al, 1995).  
Work underdone by Nourani et al. showed there to be a link between PDR5 and HXT11 
drug resistance due to fact they are both regulated by the transcription factors Pdr1p and 
Pdr3p. Deletions of the HXT11 and HXT9 genes results in drug resistance, whereas Hxt11p 
overproduction results in increased sensitivity to the drugs cycloheximide and 4-




1.11 The role of cofilin in the regulation of actin 
Cofilin-1 is a 20 kDa protein involved in the depolymerisation of actin filaments in the 
cytoskeleton. It binds to the F-actin when it is bound to ADP, destabilising actin filaments 
and promoting their disassembly. This helps to create a pool of free actin monomers that 
can be used to create new actin filaments. As such, cofilin is not only seen to have a role in 
the depolymerisation of actin, but a role in the polymerisation as well. The role of cofilin in 
either assembly or disassembly of actin filaments is dependent on its concentration relative 
to the actin subunits, with the bias towards disassembly at low concentrations and 
assembly at high concentrations (Bamburg & Bernstein, 2010). Cofilin can be activated by 
actin interacting protein-1, Aip1, and also the cyclase associated protein-1, CAP1. The 
negative regulation of cofilin occurs through phosphorylation, with the protein being 
inactivated of phosphorylated at the terminal serine-3 residue.  
Cofilin has been shown interact with VDAC (Porin) in mammalian cells. When HL-60 
promyelocytic leukaemia cells were treated with the protein kinase inhibitor staurosporine 
to induce apoptosis, cofilin was seen to translocate to the mitochondria (Chua et al, 2003). 
It is hypothesised that cofilin has a role in the regulation of apoptosis through interaction 
VDAC (Leadsham et al, 2010). Cofilin has also been shown to play a role in drug resistance 
in cancer cells, with the phosphorylation of cofilin-1 being linked to HDAC inhibitor 
resistance in hepatocellular carcinoma cells (Liao et al. 2016). Phosphorylation of cofilin by 
ERK1/2 prevented interaction with the pro-apoptotic signal Bcl-2-associated X protein 
(BAX), preventing its translocation to the mitochondria (Liao et al. 2016).  
Saccharomyces cerevisiae is an ideal model organism for studying drug resistance due to 
their fast doubling time and being easy to genetically manipulate. The genome of S. 
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cerevisae has been completely sequenced and is available on the Saccharomyces genome 
database (SGD) (www.yeastgenome.org/), along with information about individual genes 
and their interactions. In addition, S. cerevisae has a large number of genes that are 
conserved in humans, two of which are the voltage-dependant anion channels, Porin 1 and 
Porin 2. Porin 1 is a homologue of the mammalian protein VDAC1 and is non-essential in S. 
cerevisae, allowing it to be knocked out without being lethal to the cell. 
 
1.12 Aims of this study 
One minor component of the lipid membrane is the secondary signalling molecule 
phosphatidylinositol 4, 5-bisphosphate (PI45P2) which is a substrate for several proteins 
involved in signalling including the protein cofilin-1. Previous work by Kent Fungal Group, 
under the supervision of Campbell Gourlay, have shown changes in the charges on the 
surface of Cofilin-1 to have a role in drug resistance, through interaction with the 
mitochondria. 
A number cof-1 mutants display increased levels of respiration and peroxisomal fatty acid 
ɴ-oxidation, as well as the upregulation of numerous ABC and lipid transport transporters, 
included those known to have a role in drug resistance, such as PDR5, PDR10 and PDR15 
(Figure 1.5). One such mutation is the cof1-6 mutation, in which residues at Asp18 and 













In this study, we aim to determine the involvement of porin, the mitochondrial membrane 
pore, in the drug resistance seen in the S. cerevisiae mutant cof1-6. We also look to discover 
which, if any, of Pdr5, an ABC transporter, Rsb1 a lipid transporter, or Pox1, involved in 
Beta-oxidation within the peroxisome, are involved in drug resistance within the cof1-6 
mutant. We hoped that these investigations would expand our understanding of the 
control of drug resistance in yeast cells, with broader implications in other eukaryotic 
systems. 
 
Figure 1.5 Pathways upregulated in the cof1-6 cofilin mutant. The cof1-6 mutant displayed elevated levels of 
respiration, ɴ-fatty acid oxidation, as well as the upregulation of numerous ABC and lipid transport transporters, 










Figure 1.6 Mutations in cofilin in S. cerevisiae compared to other organisms. Here we look at the cof1-6 mutant in 


















2.1 Growth Media  
All media and agar was sterilised for 15 minutes at 121oC in an autoclave. All water used in 
the making of media, agar and buffers was sterile MilliQ water. 
Liquid cultures of yeast strains were grown in either YPD (1% Yeast extract (Difco), 2% 
Bactopeptone (Difco) and 2% Dextrose (Fisher Scientific)) or SD media (0.675% Yeast 
Nitrogen base without amino acids (Formedium), yeast synthetic dropout supplement 
without specific amino acid (Formedium) added as per ƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌƐ ?ŐƵŝĚĞůŝŶĞƐ ? and 
2% Dextrose (Fisher Scientific)) overnight on a 30oC rotary shaker at 180 rpm unless 
specified otherwise. E. coli were grown in YT media (0.5% Yeast Extract (Difco), 1% Tryptone 
(Difco), 1% Sodium Chloride (Fisher)) and shaken at 180 rpm overnight at 37oC. Solutions 
made up by percentage were done so by weight/volume (w/v) unless specified otherwise. 
Strains and transformants were also grown on culture plates, made up as the media with 
the addition of agar (Oxoid) at 4mg/ml. Agar used for spotting assays was autoclaved and 
cooled down to 50oC, divided into 40ml aliquots and the drug concentrations required were 
added before pouring. 
2.2 Yeast strains and growth conditions 
The strains used are listed in Table 2.1.  Primers used to generate knockout strains and 
verify correct ablation of the target gene are listed in Table 2.2. Plasmids used in this study 





Strain Genotype Reference 
CGY1260 Ddɲ ura3-52, his3D200, leu2-3,112, lys2-801, 
COF1::LEU2 
Kotiadis et al, JCS 2012 
CGY1261 Ddɲ ura3-52, his3D200, leu2-3,112, lys2-801, 
cof1-6::LEU2, ȴƉŽƌ ? 
A kind gift from Prof. 
Manuela Corte Real 
(University of Minho, 
Braga, Portugal) 
CGY1264 Ddɲ ura3-52, his3D200, leu2-3,112, lys2-801, 
cof1-6::LEU2,  
Kotiadis et al, JCS 2012 
CGY1265 Ddɲ ura3-52, his3D200, leu2-3,112, lys2-801, 
cof1-6::LEU2, ȴƉŽƌ ? 
A kind gift from Prof. 
Manuela Corte Real 
(University of Minho, 
Braga, Portugal) 
1252 Ddɲ ura3-52, his3D200, leu2-3,112, lys2-801, 
COF1::LEU2 ?ȴƌƐď ? ? ?hZ ? 
This study 
CGY1254 Ddɲ ura3-52, his3D200, leu2-3,112, lys2-801, 
COF1::LEU2 ?ȴƉŽǆ ? ? ?hZ ? 
This study 
CGY1255 Ddɲ ura3-52, his3D200, leu2-3,112, lys2-801, 
cof1-6::LEU2 ?ȴƉŽǆ ? ? ?hZ ? 
This study 
CGY1257 Ddɲ ura3-52, his3D200, leu2-3,112, lys2-801, 
COF1::LEU2 ?ȴƉĚƌ ? ? ?hZ ? 
This study 
CGY1258 Ddɲ ura3-52, his3D200, leu2-3,112, lys2-801, 
cof1-6::LEU2 ?ȴƉĚƌ ? ? ?hZ ? 
This study 
Table 2.3 Strains used in this study. 
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Table 1.1 Primers used in this study. 
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Plasmid Description Selective 
Marker 
Supplier 
PIKD493 RSB1-LacZ plasmid. LacZ gene cloned into 
the XhoI-SmaI site. RSB1 promoter cloned 
into XhoI site. 
HIS3 (Ikeda et al.) 
PCG633 Made by Gateway expression system. POR1 
was inserted into pAG416 which contains a 
CEN origin of replication with a GPD 
promoter. 
URA3 CWG 








2.3 Antibodies used in this study 
In order to detect proteins of interest by western blot, the following primary and secondary 
antibodies were used. 
Primary antibody used for Pdr5 detection: Rabbit anti- Pdr5, a gift from Karl Kuchler, 
Department of Molecular Genetics, University and Biocenter of Vienna, and was used at a 
dilution of 1/2000. 
Table 2.3 Plasmids used in this study. 
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Primary antibody used for Slt2 detection: Rabbit Anti-Phosphpo-44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (Cell Signalling, catalogue number #4370) and was used at a dilution of 
1/2000. 
Primary antibody used for Porin detection: Mouse anti-VDAC1/Porin (Abcam, catalogue 
number # 16G9E6BC4) and was used at a dilution of 1/2000. 
Primary antibody used for actin detection: Sheep anti-actin, a kind gift from Prof. John 
Cooper (Washington University) and was used at a dilution of 1/2000. 
Secondary antibody used for Pdr5 and Slt2 detection: Goat Anti-Rabbit IgG HRP (Sigma, 
catalogue number #A0545) and was used at a dilution of 1/5000. 
Secondary antibody used for Porin detection: Goat Anti-Mouse IgG HRP (Sigma, catalogue 
number #A4416) and was used at a dilution 1/5000. 
Secondary antibody used for actin detection: Donkey Anti-sheep IgG HRP (Sigma, 
catalogue number A3415) and was used at a dilution of 1/5000. 
 
2.4 Growth Analysis 
Strains were grown overnight in 5ml of YPD, shaking in a rotary shaker at 180rpm at 30oC. 
The absorbance at OD600 of the overnight culture was measured in the morning using an 
Eppendorf Biophometer plus. The overnight cultures were inoculated to a starting OD600 of 
0.1 in a sterile 24 well plate (Greiner) in technical triplicates. The plate was measured for 




Cycle Time 1800 seconds 
Flashes Per Well 3 
Excitation 600 nm 
Shaking Frequency 400 rpm 
Shaking Mode Double Orbital 
Additional Shaking Time 30 Seconds before Each cycle 
Temperature 30°C 
Positioning Delay 0.5 Seconds 
 
 
2.5 Plasmid purification from E. coli 
E. coli strains containing plasmids used in this study were grown overnight at 37oC on a 
rotary shaker, shaking at 180 rpm in YT with ampicillin at 1mg/ml. The QIAprep Spin 
Miniprep Kit was used to extract and concentrate the desired plasmids as per the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ? 
 
2. 6 Molecular Biology Methods 
2.6.1 Polymerase Chain Reaction 
PCR was done in order to amplify linear DNA that was used to knockouts genes in the wild-
type and cof1-6 background. The PCR mix contained Oligonucleotides, nucleotides, a DNA 
template and Taq polymerase and the reaction was done in a C1000 Thermocycler (Biorad). 
The Thermocycler used different temperatures for different time periods to initiate the 
processes of denaturation, elongation and annealing required to make single stranded DNA 
Table 2.4 The protocol used to measure growth rate in the SPECTROstar nano plate reader. 
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fragments. ThĞƉŽůǇŵĞƌĂƐĞǁŽƌŬĞĚĨƌŽŵƚŚĞ ? ?ƚŽ ? ?ĞŶĚŽĨƚŚĞEƚĞŵƉůĂƚĞ ?ŝŶďĞƚǁĞĞŶ
where the two primers bound, using the nucleotides to produce the fragments. The 
fragments act as DNA templates to make more fragments that are copies of the DNA 
fragment in between the two nucleotides that have bound to the DNA template first used. 
A standard 50µl PCR mix used was as follows: 
35µl Sterile MilliQ H20 
1µl Forward Primer 
1µl Reverse Primer   
5µl DNA template (20ng/ml) 
1µl 100mM dNTPs (INVITROGEN) 
5µl 10x Buffer (INVITROGEN) 
1.5µl 100mM MgCl2 (INVITROGEN) 









The program for the C1000 Thermocycler was as follows: 
95oC for 5 minutes: Denaturation of template DNA 
95oC for 40 seconds: Short Denaturation 
56oC for 40 seconds: Annealing  
72oC for 1 minute 40 seconds: Elongation 
72oC for 15 minutes: Final Elongation 
 
The program for the C1000 Thermocycler for the control PCR was as follows: 
95oC for 5 minutes: Denaturation of template DNA 
95oC for 40 seconds: Short Denaturation 
55oC for 40 seconds: Annealing  
72oC for 40 seconds: Elongation 
72oC for 15 minutes: Final Elongation 
 
2.6.2 Yeast Transformation 
Yeast transformations were used to introduce new DNA into parental yeast cells, either to 
knockout genes or introduce plasmids. A 5ml overnight culture of yeast cell was grown in 
either YPD or SD media overnight at 30oC shaking in a rotary shaker at 180rpm. 1ml of 
overnight culture was then taken and added to a 1.5ml sterile Eppendorf tube. Cells were 
harvested for 1 minute at 10000rpm in a table top centrifuge before being washed in 1ml 
Repeat for 30 cycles 
Repeat for 30 cycles 
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of TE (10mM Tris-Cl pH 7.5, 1mM ethylenediaminetetraacetic acid (EDTA)). The cells were 
then washed in 1ml of 0.1M Lithium Acetate (LiOAc) in 1x TE. The cells were next 
resuspended in 100µl 0.1M LiOAc in 1 xTE. Next, 0.1mg of a 10mg/ml stock of single 
stranded DNA from heron sperm, that had been boiled at 90oC for 10 minutes and frozen, 
was added. The solution was mixed gently and either 2µl of plasmid (200ng), or 15µl 
(1.5mg) of single stranded DNA made by PCR, was added followed by 700µl of 40% 
Polyethylene Glycol (PEG) in 1x TE. The solution was mixed by rotation at room 
temperature for 60 minutes before undergoing a heat shock at 42oC for 15 minutes. The 
cells were then harvested for 1 minute at 10000 rpm using a table top centrifuge and re-
suspended in 100µl of sterile MilliQ H2O. The sample was then plated on the appropriate 
selective media plate and left for 3 days at 30oC until individual colonies formed. These 
colonies were then re-streaked onto selective media plates and incubated at 30oC for 2-3 
days. 
 
2.6.3 Agarose gel electrophoresis  
In order to make a 1% agarose gel, 0.5g of agarose (Melford) was dissolved in 50ml of TAE 
buffer (10M EDTA, 0.04M Tris-acetic acid (v/v)). The agarose was dissolved in TAE by 
heating, making sure all the agarose was fully dissolved. Ethidium bromide was added at 
0.05ʅl/ml and the gel was poured into casts (Biorad) and left to cool for 30 minutes. The 
gel was then added to an electrophoresis tank (Biorad) and covered in 1x TAE. The samples 
(2µl sample, 2µl 6x Loading Dye. 8µl sterile H2O )ǁĞƌĞĂĚĚĞĚƚŽƚŚĞŐĞů ?ĂŶĚ ?ʅůŽĨ ?<ďA?
DNA ladder (ThermoFisher) was added to the first gel well. The ladder was used to 
determine the correct molecular weight of the sample DNA bands. The gel was then run 
43 
 
for 90V for 30 minutes until the ladder had reached at 75% down the gel. The gel was then 
visualised in a FLA-5100 gel imaging system (Fujifilm) to see and capture the location of the 
DNA bands. 
 
2.7 Protein Analytical Methods 
2.7.1 Whole Cell Protein extraction 
Cells were grown up overnight in YPD or SD media to mid log phase in a 30oC rotary shaker 
before protein samples were prepared by harvesting 1 x 108 cells and re-suspended in 
200µl of lysis buffer (0.1 M NaOH, 0.05 M EDTA, 2% SDS, 2A?ɴ-mercaptoethanol). These 
samples were then heated for 10 min at 90oC before 5µl of 4M acetic acid was added and 
the samples were vortexed for 30 s. They were then incubated at 90oC for a further 10 min 
before 50ml of loading buffer (0.25 M Tris-HCl pH 6.8, 50% Glycerol, 0.05% 
Bromophenolblue) was added. These samples were then either frozen at -20oC or used 
immediately. To use the samples for western blotting, the lysate was cleared through 
centrifugation and the supernatant loaded into the SDS PAGE gel. 
 
2.7.2 Preparation of polyacrylamide gels. 
All the samples were run on a 10% SDS PAGE gel composed of both a stacking (5% 
Acrylamide, 240nM 0.5 Tris Buffer, 0.07% TEMED, 0.23% APS) segment on top of a resolving 
segment (10% Acrylamide, 126mM 1.5 Tris Buffer, 0.07% TEMED, 0.12.5% APS). The SDS-
PAGE gels were made up in a glass cassette (Biorad) 0.75mm thick. The first layer to be 
poured was the resolving layer, 6.5cm long from the bottom of the cassette. 1ml of 
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isopropanol was added to ensure the resolving layer was free from bubbles and level after 
the gel had been cast. After being left for 20 minutes to set, the stacking segment was 
added up to the top of the cassette and a comb with the correct number of wells was placed 
into the top of the cassette. The gel was then left to set for a further 20 minutes. 
 
2.7.3 Protein gel electrophoresis 
dŚĞƐĂŵƉůĞƐǁĞƌĞƚĂŬĞŶĂŶĚ ? ?ʅůŽĨĞĂĐŚǁĂƐůŽĂĚĞĚŝŶƚŽƚŚĞĂĐƌǇůĂŵŝĚĞŐĞůand run for 
90V for around 30 minutes attached to a Biorad power supply, until the samples had passed 
through the stacking gel. The samples were then run at 120V for a further 2 hours until they 











Figure 2.1 Breakdown of the Trans-Blot SD with Gel Sandwich taken from the Trans-Blot SD user manual. 
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2.7.4 Semi-dry protein transfer 
The resulting separated proteins were transferred onto a PVDF membrane through semi 
dry transfer using a Biorad Trans SD machine.  Two pieces of blotting paper of equal size (8 
x 9cm) were wetted in transfer buffer (50ml 10x transfer buffer, 100ml methanol, 350ml 
distilled H2O) and the PVDF membrane (8x9cm) was wetted in methanol before being 
ƐŽĂŬĞĚ ŝŶ ƚƌĂŶƐĨĞƌ ďƵĨĨĞƌ ĨŽƌ  ? ? ŵŝŶƵƚĞƐ ? dŚĞ ƚƌĂŶƐĨĞƌ ǁĂƐ ůĂǇĞƌĞĚ ŝŶ Ă  ‘ƐĂŶĚǁŝĐŚ ?
arrangement with a piece of blotting paper placed first followed by the PVDF membrane, 
the SDS PAGE gel, and finally the second piece of blotting paper, ensuring all air bubbles 
are rolled out (Figure 2.1). The transfer was run at 25V for 30 minutes per gel. 
 
2.7.5 Western Blot detection Using Enhanced Chemiluminescence (ECL) 
After semi-dry transfer, the PVDF membrane was blocked in blocking buffer (5% semi 
skimmed milk powder, 1x Phosphate Buffered Saline +0.2% Tween 20 (PBS/T)) for 45 
minutes at room temperature on a rotary shaker. The membrane was then briefly rinsed in 
PBS/T and then placed in a 50ml Sarstedt tube with 5ml blocking solution and with primary 
antibody at a 1:2000 dilution. The tube was left to incubate overnight in a 4oC cold room 
on a roller mixer. Next the membrane was removed and briefly washed in PBS/T twice 
before being washed for 15 min followed by two 5 min washes in PBS/T. The membrane 
was next placed in a 50ml Sarstedt tube with 5ml blocking buffer with a horseradish 
conjugated secondary antibody at a 1:5000 dilution. The tube was left to incubate at room 
temperature for 30 min on a roller mixer. 
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After the incubation period was up the membrane was briefly washed twice in PBS/T twice 
before being washed for 15 min followed by three 5 min washes in PBS/T. The membrane 
was transferred to PBS. Two ECL solutions were made up as follows: 
Solution I (2.5 mM luminol, 0.396 mM coumaric acid, 0.1 M Tris.HCL pH 8.5). 
Solution II (6.266 mM hydrogen peroxide, 0.1 M Tris.HCL pH 8.5). 
The solutions were mixed at a 1:1 ratio and the membrane was drained of PBS. The mixed 
solutions were then poured on the membrane and left for exactly one minute before the 
excess was removed and the membrane was transferred to Saran wrap. The membrane in 
Saran wrap was transferred to a Syngene G:Box for imaging.  
 
2.8 Beta Galactosidase Assay 
1 x 107 cells, equating to an optical density of 0.5, were harvested at 10000rpm for 1 
minute. The cells were then washed in 500µl Z Buffer (60mM Na2PO4, 40mM NaH2PO4, 
10mM KCl, 1mM MgSO4, 50mM ɴ-mercaptoethanol (Sigma Aldrich)). The pellet was then 
re-suspended in 600µl of Z Buffer and incubated at 28oC for 30 minutes. Next, 150µl of 
4mg/ml ONPG solution (Sigma Aldrich) was added and mixed by hand before being 
incubated at 30oC until the solution developed a yellow colour. The reaction was stopped 
by the addition of 400µl of 1.5M Na2CO3 and centrifuged for 30 seconds at 13000rpm to 
pellet cells. Finally, 1ml of supernatant was then taken and the optical density measured at 
420nm, 550nm and 600nm. In order to normalise the results when biological repeats were 
done, the measurements at 420nm were divided by the time taken for the colour to 
develop in each assay. The resulting values were then averaged and plotted on bar charts. 
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2.9 Spotting Assay 
Cells were grown overnight in 5ml of YPD or SD media to mid log phase at 30oC in a rotary 
shaker before the optical density was recorded. Plates containing the required drug were 
prepared as follows. YPD agar was autoclaved and cooled down to 50oC, divided into 40ml 
aliquots and the drug concentrations required were added before pouring. The plates were 
then allowed to set before being dried to remove all moisture from the agar surface. 
Using a metal spotting plate which had been autoclaved at 121oC for 15 minutes and dried 
in a drying oven overnight, we inoculated the cells to a starting OD600 of 0.1 in 550µl of 
sterile MilliQ H2O in the first well of the spotting plate. Next, 50µl of liquid from the first 
well was diluted in 500µl of sterile MilliQ H2O in the second well. This process was repeated 
in the third well, with 50µl of liquid being discarded from the third well to make a total 
volume of 500µl in each well. Serial dilutions, as described above, were done for each of 
the samples on the spotting plate.  
A metal spotting plate stamp was sterilised in 100% ethanol, flamed and let to briefly cool 
before being placed into the spotting plate. The stamp was then placed on each agar plate, 
sterilised and left to cool in between each plate. The plates were then left to dry before 
being incubated at 30oC for 2-3 days. Plates were then scanned using a CanoScan 4400F 








2.10.1 Sample Preparation  
GFP-labelled yeast cells were grown in 5 ml SD media overnight at 30oC before being 
inoculated in the morning for YPD media at 30oC, both on a rotary shaker at 180 rpm. The 
cells were then left for 24 hours to view the strains at stationary phase. To visualise the 
cells, a thin layer 1% agarose in water was poured on a sample slide before being dived into 
4 even slices. Next, 2µl of sample was placed on each slice and a covered using a 0.4mm 
cover slip. A drop of immersion oil was added to the surface of the cover slip ready to be 
visualised. 
 
2.10.2 FM4-64 Staining 
Cells were grown to exponential and stationary phase overnight in SD medium at 30oC in 
5ml of culture. The strains were then spun down and re-suspended in 500µl of YPD and 
FM4-64 stain added to a final concentration of 8µM. The strains were then incubated at 
30oC in the dark for 30 minutes before being spun down again and washed in 500µl of YPD. 
They were then spun down again and re-suspended in 1ml of YPD, before being transferred 
into a culture tube and incubated at 30oC in the dark in a rotary shaker for 30 min. Next, 
the cells were spun down and re-suspended in 30µl PBS, ready to be visualised. 
 
2.10.3 Visualisation PI3P and PI4P Sensors 
To visualise the images an Olympus IX81 microscope was used coupled a Cool Led pE-4000 LED 
illumination system. The GFP filter used produced excitation at 488(+/-10 nm) and emission at 512 
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(+/- 10 nm). The RFP filter used produced excitation at 555 (+/- 10 nm) and emission at 584 (+/- 10 
nm). The camera used was an Andor Zyla 5.5CMOS camera linked to Micromanager control 
software. The images were visualised at 100x objective with 20ms exposure in the case of GFP 



















3. Drug resistance linked to the Cofilin mutant, cof1-6. 
Previous research has found links between the function of mitochondria and the drug 
resistant phenotype shown by non-lethal cofilin-1 mutants. A correlation was found 
between increased respiration and resistance to a range of drugs. Although the exact 
mechanism has yet to be determined, research indicated a mediating factor was the charge 
of the cofilin surface.  The multi drug resistance was associated with an upregulation in 
drug pumps and plasma membrane lipid transporters. Research has also shown that 
expression of the cofilin-1 mutant cof1-6 allele, results in the upregulation of genes 
involved in fatty acid ɴ-oxidation within the peroxisome. As a result, we hypothesise that 
cofilin links signalling from the plasma membrane to a novel stress response pathway that 
controls the expression of drug resistance. One possibility is that response to a change in 
charge in the lipid membrane due to damage by antifungal drugs activates the cofilin 
sensing mechanism and a drug resistance response. We sought to investigate the role of 
mitochondria, fatty acid ɴ-oxidation and membrane transporters in cofilin medicated drug 
resistance. Initially we deleted the mitochondrial outer membrane protein porin, encoded 









3.1 Itraconazole resistance in the cof1-6 mutant 
Cells expressing cof1-6 had much better growth in the presence of Itraconazole when 
compared to the wild-type (Figure 3.1). Knocking out the POR1 gene in the cof1-6 
background was sufficient to re-sensitize cells to itraconazole treatment. This indicates a 







The cof1-6 mutant has also been seen to display elevated levels of respiration, fatty acid 
beta-oxidation, as well as increased ABC and lipid transporters. We set about studying 
three genes that corresponded to each of these phenotypes. The ABC transporter Pdr5 is 
the most prevalent drug transporter in the cell and has been seen to be linked to drug 
resistance. Pox1 is an enzyme required to complete fatty acid beta oxidation within the 
Figure 3.1 cof1-6 resistance to Itraconazole is dependent upon POR1. Strains were grown overnight to mid-log 
phase in YPD before being plated on either YPD plates (Left) or YPD with 4.4mM Itraconazole (Right). The strains 
were plated at optical density of 0.1 and diluted 10-fold in a serial dilution and left to grow for 48 hours. 
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peroxisome, converting acyl-CoA into 2,3-dehydroacyl-CoA, and Rsb1 is a sphingoid long 
chain base transporter. 
 
3.2 Generation of RSB1, POR1, POX1 and PDR5 knockouts in the cof1-6 background  
Our published result suggests that respiratory function within the mitochondria and beta 
oxidation, as well as various ABC and lipid transporters, are increased within the cof1-6 
mutant. To determine if one or more of these phenotypes is involved in drug resistance, 
we knockout out one gene from each. These genes were the ABC transporter PDR5, POX1 











Figure 3.2 Confirmation of knockout clones by PCR or Western Blot. The ȴrsb1 and ȴƉŽǆ ? strains were confirmed by 
PCR using control primers and then visualised using gel electrophoresis as seen in image A and B. The ȴpdr5 strains 
were confirmed by western blot using a Pdr5 specific rabbit antibody. The labelling indicates the number of the clone 






We next set about knocking out these genes of interest. To do this we amplified a cassette 
containing URA3 flanked by targeting sequences to promote gene deletion by homologous 
recombination. Linear DNA designed to delete each target gene was amplified by PCR, 
verified by gel electrophoresis and transformed into both the wild-type and cof1-6 mutant 
strains. Colonies arising on selective plates were isolated and tested for correct gene 
deletion by PCR using a primer located within the selective marker gene and one 
downstream of the target gene. In the case of the PDR5 knockout, a western blot using an 
anti-Pdr5 rabbit polyclonal antibody was carried out to confirm deletion. Out of all of the 
clones tested we managed to get positive clones for the deletion of POX1 and PDR5 in both 
the wild-type and cof1-6. For RSB1 we only succeeded in acquiring knockouts in the cof1-6 
background. These confirmed knockouts were taken forward for further testing. POR1 had 
already been deleted in wild type and cof1-6 cells and were a kind gift from the lab of Prof 
Manuela Corte Real (University of Minho, Braga, Portugal). 
 
3.3 Elevated Rsb1 expression in Cof1-6 dependant on Por1 
The Rsb1 lipid transporter protein is crucial in the movement of sphingoid long chain bases 
from the cytoplasmic to the extracytoplasmic side of the lipid cell membrane. Previous 
microarray data from our group suggested that Rsb1 expression is increased upon 
expression of the cof1-6 allele (unpublished observations). To confirm that Rsb1 is 
upregulated wild type and cof1-6 expressing strains, were transformed with a plasmid 
containing the RSB1 promoter coupled to a LacZ gene. LacZ codes for beta galactosidase 
which cleaves lactose into glucose and galactose. As part of the assay, ONPG is used, which 
when beta galactosidase is present, is cleaved into galactose and ortho-nitrophenol. Ortho-
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nitrophenol has a yellow colour which can be measured at 420nm using a 
spectrophotometer. As a positive control, an NRG1 knockout strain was used as it Nrg1 is a 
repressor of Rsb1 expression. The results were normalised by the time taken for the colour 







The results of the beta-galactosidase assay showed a clear increase in RSB1 promoter 
activity in cof1-6 mutant cells in comparison to the wild type (P value = <0.0001). This in in 
line with our unpublished the microarray data and may indicate the involvement of Rsb1 
and the transport of sphingoid long bases in cofilin mediated drug resistance. The ȴƉŽƌ ? 
strain showed no significant difference in expression levels in comparison to the wild type 
Figure 3.3 Beta-Galactosidase assay to determine Rsb1 expression. The wild-type, ȴpor1, cof1-6 and cof1-6 ȴpor1 strains were 
transformed with a plasmid containing the Rsb1 promoter linked to the LacZ gene. Deletion of NRG1 is known to lead to an 
increase in Rsb1 promoter activity and so was used as a positive control. Results were normalised by assay run time and analysed 
using a T-test comparing each strain to the wild-type *** corresponds to a P value < 0.0001 when compared to the wild-type. 
*** 
*** 
ȴŶƌŐ ? ȴƉŽƌ ? cof1-6 cof1- ?ȴƉŽƌ ? WT 
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with a P value = 0.1149. There was also no significant difference in the expression levels 
between the wild type and cof1-6 ȴƉŽƌ ? mutant (P value = 0.2288) showing that the Rsb1 
elevation seen in the cof1-6 mutant is dependent on the presence of porin.  
Rsb1 levels have been shown to be responsive to changes in the charge of the plasma 
membrane. We hypothesised that commonly used antifungals may alter plasma 
membrane charge and activate Rsb1 expression through activating the RIM101 pathway. 
To investigate whether drug exposure is sufficient to activate Rsb1 expression we exposed 
cells transformed with the RBS2-lacZ reporter to different concentrations of the drugs 






Figure 3.4 Beta-Galactosidase Assay showing the effect of Amphoterecin B and Itraconazole on Rsb1 promoter 
activity. Overnight cultures of the strains were inoculated for four hours in either amphotericin B at 0.15µg/ml or 
0.3 µg/ml, or itraconazole at either 2.2µM or 4.4 µM. A beta galactosidase assay was then done as described in the 
materials and methods section. There was no significant difference in expression between the wild-type control 
and the treated strains, showing Rsb1 expression is not induced through antifungal exposure. There was also no 




The results showed no significant difference in Rsb1 expression between the wild-type 
control and the treated wild-type strains treated with amphotericin B at 0.15 ʅg/ml (P value 
= 0.3366) or 0.3 ʅg/ml (P value = 0.471). There was also no significant change in Rsb1 
expression between the wild-type control and wild-type treated with itraconazole at 2.2ʅM 
(P value = 0.5938) and 4.4ʅM (P value = 0.9603). This indicated that elevated Rsb1 







Figure 3.5 Beta-Galactosidase Assay showing the effect of alkaline pH on Rsb1 expression. Strains were either 
inoculated for 4 hours from an overnight culture in YPD or YPD with 100mM Tris Buffer at pH8. These strains were 
then used for a beta-galactosidase assay as described in the materials and methods section. * corresponds to a P 
value = < 0.05, ** corresponds to a P value = < 0.01. ȴnrg1, cof1-6, and cof1-6 Al were significant compared to the 









WT WT Al 
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Alkaline exposure can be detected by the Rim21 sensor on the cell membrane, activating 
the RIM101 pathway and inducing genes involved in cell wall synthesis such as Rsb1. 
Rim101 indirectly activates Rsb1 expression by repressing Nrg1 which in turn represses 
Rsb1 (Ikeda et al. 2008). The determine if Rsb1 promoter activity expression would differ 
in the wild-type and cof1-6 mutant in response to an alkaline pH exposure, a beta 
galactosidase assay was conducted after growing the cells into early log phase in YPD with 
100mM Tris buffer at a pH of 8. The results showed the same trend found in the untreated 
strains, with the cof1-6 mutant showing elevated levels of Rsb1 expression, significantly 
more than the wild-type. However, there was no significant difference between the 
expression levels in the wild-type, porin deletion and cof1-6 porin deletion strains. If Rsb1 
promoter activity was induced by alkaline pH exposure, it would have been expected that 
the wild type would have shown raised levels of Rsb1 when exposed to alkaline conditions 
but this was not the case (P value = 0.3709). When compared to the untreated strains, the 
wild-type, cof1-6 and cod1-6 ȴƉŽƌ ? strains grown in alkaline conditions no significant 
difference in Rsb1 promoter activity under the conditions used (P value = > . The ȴƉŽƌ ? 
deletion grown in alkaline conditions showed significantly reduced Rsb1 activity although 
this does not appear to affect drug resistance (P value = 0.0122). This may be explained by 













To see if exposure time to the HEPES buffer affected was having an effect on the expression, 
the HEPES buffer at pH 8 was added either at the beginning of the 4hour inoculation period, 
or after 2 hours. The resulting data in Figure 3.6 showed that increasing the cell density 
had significant effect on the amount of Rsb1 expressed in all cases, including the positive 
control (all P values = > 0.05). Adding the HEPES buffer at different time points had no 
significant effect on Rsb1 expression when compared to the untreated wild-type in YPD 
alone (all P values = > 0.05).  
 
Figure 3.6 Beta-Galactosidase assay showing the effect of different starting cell densities and alkaline pH on Rsb1 
expression. For the assay, the wild-type was either used at a starting OD600 of 0.5 or 1.0. In addition, HEPES buffer 
at pH 8 was also added at the beginning of the 4 hour incubation, after 2 hours, or not at all. A beta galactosidase 
assay was then done as described in the materials and methods section. ** corresponds to a P value = < 0.01. 
** 
** 








The RSB1 knockout in the wild type background also showed no difference to the non-deleted wild-
type strain, both showing inhibited growth in the presence of itraconazole at 4.4ʅM, flucytosine at 
249.6ʅM and amphotericin B at 0.6ʅg/ml (Figure 3.7). Deleting RSB1 showed had no effect on drug 
resistance in the wild-type background, however as we did not have the cof1-6 ȴrsb1 strain, it 
cannot be confirmed if Rsb1 is involved in drug resistance in the cof1-6 mutant.  
 
3.4 The effects of deleting PDR5 on cofilin mediated drug resistance  
We tested whether loss of the ABC transporter PDR5 led to changes in multi-drug resistance 
using ȴpdr5 in both the wild-type and cof1-6 background. Once the deletions had been 
acquired, they were used in a spotting assay to see how they would respond to different 
classes of drugs at different concentrations. 
Figure 3.7 Spotting assay showing no change in resistance between resistant wild-type strain and its 
corresponding RSB1 deletion. Overnight cultures of the wild-type, cof1-6 and wild-type ȴrsb1 strains were diluted 
to a starting OD600 of 0.1, and serially diluted 1 in 10. They were then grown for two days at 30oC on YPD plates in 








The cells were diluted to an optical density (OD600) of 0.1 and then diluted 1 in 10 in three 
subsequent serial dilutions. They were assayed in the presence of the azole Itraconazole, 
the polyene amphotericin B, and the nucleoside analogue flucytosine. As expected, 
removing the PDR5 gene in the cof1-6 strain reversed the drug resistant phenotype 
normally seen in the cof1-6 strain (Figure 3.8). This was expected as azoles are known to 
be substrates for ABC transporters.  We also noticed that deleting PDR5 in both the wild-
type and cof1-6 strains caused the strains to become resistant to both flucytosine and 
amphotericin B (Figure 3.8). This was unexpected as we hypothesised that knocking out 
the most prevalent drug efflux pump in the cell would lead to sensitivity to amphotericin B 
but this was not the case. An explanation for this could be that when PDR5 is deleted, it 
allows other drug efflux pumps within the cell such as Pdr10 and Pdr15 to be upregulated 
Figure 3.8 Spotting assay showing the effect of deleting PDR5 on the wild-type and cof1-6 strains. Overnight 
cultures of the wild-type, cof1-6, wild-type ȴpdr5 and cof1-6 ȴpdr5 strains were diluted to a starting OD600 of 0.1, 
and serially diluted 1 in 10. They were then grown on YPD plates for two days at 30oC in the presence of 
itraconazole, flucytosine and amphotericin at the different concentrations shown. The cof1-6 strain loses resistance 
to Itraconazole but gains increased resistance to Amphotericin B at both 0.6ʅŐ ?ŵůĂŶĚ ? ? ?ʅŐ ?ŵů ? 
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and these have the ability to remove flucytosine and amphotericin B from the cell more 






Our data suggest that deletion of PDR5 leads to sensitivity to itraconazole but resistance to 
flucytosine.  Itraconazole and Flucytosine resistance is often seen in tandem so further 
study was required in the PDR5 knockout to see why this was not the case. It has been 
reported that resistance to drugs that reduce growth by targeting anabolic processes such 
as RNA or DNA biosynthesis which is inhibited by flucytosine, can occur in strains simply 
because they grow more slowly. To test whether this may be the case for cells lacking PDR5 
we tested the effects of removal of this ABC transporter on growth rate. Surprisingly in all 
Figure 3.9 Growth curve showing the growth rate of the PDR5 deletions compared to the wild-type and cof1-6 
strains. The strains were grown overnight and inoculated to a starting OD600 of 0.1 in YPD. They were then 
measured at 30 minute intervals for 27 hours. The PDR5 deletions showed increased growth rate and a higher final 
density than the wild-type and cof1-6 strains. 
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cases the deletion of PDR5 led to a dramatic increase in growth rate and led to a much 
higher final density. This suggests that Flucytosine resistance observed in PDR5 knockout 
strains does not occur as a result of reduced growth. The increased rate of growth may 
indicate that Pdr5 production requires a lot of energy or resource expenditure from the cell 
and when deleted it allows the cell to channel this energy into growth. Alternatively, Pdr5 
may be involved in signalling processes that medicate growth rate and biomass 
accumulation. The PDR5 knockouts all reached a plateau at an OD600 of 6.7, which is most 
likely when they exhausted the supplies of nutrients required or growth from the growth 
media. Alternatively, it could indicate that the ȴpdr5 strains are unable to use ethanol as a 







Figure 3.10 Spotting assay showing no change in resistance between resistant cof1-6 strain and its corresponding 
POX1 deletion. Overnight cultures of the wild-type and cof1-6, wild-type ȴpox1 and cof1-6 ȴpox1 strains were 
diluted to a starting OD600 of 0.1, and serially diluted 1 in 10. They were then grown on YPD plates for two days at 
30oC in the presence of itraconazole, flucytosine and amphotericin at the different concentrations shown. The wild 




The POX1 deletion in the cof1-6 background did not lead to measurable differences in 
resistance to the three drugs tested. The cof1-6 ȴpox1 strain seemed to be resistant to 
Itraconazole at 4.4ʅM ĂƐ ǁĞůů ĂƐ ĂŵƉŚŽƚĞƌŝĐŝŶ  Ăƚ  ? ? ?ʅŐ ?ŵů ? dŚĞ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ŽĨ
aŵƉŚŽƚĞƌŝĐŝŶĂƚ ? ? ?ʅŐ ?ŵůǁĂƐƚŽŽŚŝŐŚĨŽƌƚŚĞcof1-6 strain and so no growth was seen 
despite cof1-6 being resistant. The cof1-6 ȴƉŽǆ ? strain showed no change in growth from 
the cof1-6 indicating that the POX1 gene had no effect on the resistance of the cof1-6 strain. 
However, deleting the POX1 gene in the wild-type background seemed to result in a slight 
increase in sensitivity to flucytosine at both concentrations. 
 
3.5 Control of Pdr5 expression is not regulated by PKC or activated by lipid stress 
Our unpublished experiments (Dr. Patrick Rockenfeller, Gourlay lab) suggest that cofilin 
interacts with the PKC/MAPK cell wall integrity pathway. One possibility is that the cof1-6 
mutation leads to activation of PKC and that this signal mediates the expression of Pdr5 












 To determine if the Pkc1-mediated cell wall integrity pathway was involved in cofilin 
mediated drug resistance, we tested the wild-type, cof1-6 and associated POR1 deletion 
strains by inoculating them for four hours in YPD with either Cercosporamide, Ceramide, 
or both. Ceramide is a sphingolipid precursor that causes mitochondrial cell death in high 
doses. In this case we used ceramide to test whether lipid stress was sufficient to activate 
upregulation of a drug resistance response and whether this was mediated via PKC 
signalling.   This could be achieved by using Cercosporamide, which specifically inhibits 
protein kinase C (Pkc1).  The treated strains were also used to make protein extracts and 
run on a western blot to check for Pdr5 levels and activation of the MAPK signalling 
pathway.  
Figure 3.11 Western blot showing changes in Pdr5 expression after Ceramide and Cercosporamide treatment.  
Strains were grown up overnight in YPD before being inoculated for 4 hours in YPD with either ceramide, 
cercosporamide or both. Whole protein extracts were then taken as described in the materials and methods. Pdr5 
expression did not change in the presence of any of the treatments. Pdr5 expression was elevated in both the cof1-
6 and cof1-6 ȴpor1 compared to the wild-type but this was not affected by the treatments. Also shown is the actin 
loading control.  
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Initially we conducted we did a spotting assay to see the effect of the treatments, ceramide 
and Cercosporamide, on drug resistance phenotype (Figure 3.13). The wild-type showed 
small amounts of growth on the Itraconazole in all treatments, while being susceptible to 
both concentrations of Amphotericin B. Neither ceramide nor cercosporamide treatment 
resulted in a change in drug resistance in the cof1-6 compared to the control, with the 
strain showing resistance to Itraconazole in all treatments. Removing porin also showed no 
effect compared to the control, with the cof1-6 ȴƉŽƌ ? showing sensitivity to all the 
antifungals used regardless of treatment with cercosporamide, ceramide or both. This 
indicated that the resistance seen in the cof1-6 is not regulated by the Pkc1-mediated cell 
wall integrity pathway, and it also confirms that it is not a response to lipid stress upon 
ceramide treatment. 
To confirm the effects of ceramide and cercosporamide we also carried out a western blot 
for both Pdr5 (Figure 3.11) and for the activated form of the terminal MAPK Slt2 which is a 
protein kinase that is activated by Pkc1, and which is responsible for the activation of a 
whole plethora of genes involved in cell wall integrity.  
The Slt2 probe showed no specific binding in any of the strains or treatments, resulting in 
the blot seen in Figure 3.12. Indicating that Pck1 activity was not upregulated in response 
to the cell was stress caused by ceramide, or decreased in the presence of the Pkc1 
inhibitor, Cercosporamide. However a positive control was omitted from these 
experiments and so it remains possible that a lack detection of activated Slt2 may have 
arisen for technical reasons. Repetition of this experiment with the inclusion of a positive 
control, such as the addition of cell wall stress, would be required to confirm this. 
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The Pdr5 probe showed very little signal in the wild-type when compared to the cof1-6 and 
cof1-6 ȴƉŽƌ ? strains in all treatments, indicating that Pdr5 expression is increased in the 
cof1-6 background. The upregulation of Pdr5 in cof1-6 cells was not inhibited upon deletion 
of porin and in fact levels were significantly elevated. This result was unexpected as 






Figure 3.12 Western Blot to see Slt2 expression in strains treated with Cercosporamide, Ceramide or both. Strains 
were grown up overnight in YPD before being inoculated for 4 hours in YPD with either ceramide, cercosporamide 
or both. Whole protein extracts were then taken as described in the materials and methods.  Nonspecific binding of 
Slt2 was observed in all strains, indicating that the cof1-6 does not induce Slt2 activity through the CWI pathway in 
















Figure 3.13 Spotting assay showing the effect of Cercosporamide and Ceramide treatment on drug 
resistance. Strains were grown up overnight in YPD before being inoculated for 4 hours in YPD with 
either ceramide, cercosporamide or both. After inoculation, the strains were diluted to a starting OD600 
of 0.1, and serially diluted 1 in 10. They were then grown in the presence of itraconazole at 4.4µM and 
amphotericin B at 0.6µg/ml and 1.2µg/ml. The plates were left to grow for 2 days at 30oC.  The wild-
type and cof1-6 ȴpor1 were sensitive to both Itraconazole and Amphotericin B.  The cof1-6 mutant 
showed resistance to Itraconazole and Amphotericin B even when treated.  
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Current theories link the presence of drug transporters to the presence of the drug 
resistant phenotype. In order to determine if there was a difference in expression levels of 
Pdr5 between the wild-type and cof1-6 mutant, a western blot was undertaken. As 
predicted, the cof1-6 mutant had significantly higher elevated Pdr5 expression compared 
to the wild-type. What was more surprising was the ȴƉŽƌ ? also showed elevated expression 
of Pdr5 in relation to the wild-type, although much less than seen in the cof1-6 mutant. The 
most surprising of all, however, was the elevated Pdr5 levels seen in the cof1-6 ȴƉŽƌ ?, 
which showed the highest expression levels of any of the strains. This may suggest that 
Por1 has a down-regulatory role in Pdr5 expression, and when deleted, expression levels 
are upregulated.  It also suggests that the expression of Pdr5 regulated by por1 and the 
Figure 3.14 Western blot displaying increased expression of Pdr5 in the cof1-6 when compared to the wild-type. 
Strains were grown up overnight in YPD before a whole cell protein extract was taken as described in the materials 
and methods. Lane 1 contains the wild-type, lane 2 contains ȴpor1, lane 3 contains the cof1-6 mutant and lane 4 
contains the cof1-6 ȴpor1 mutant.  
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expression of Pdr5 in the cof1-6, are controlled through two separate pathways. We 
predicted that the presence of Pdr5 would correlate to drug resistance but this clearly is 
not the case in the cof1-6 mutants. It is more likely that por1 has a role in the activation of 
the Pdr5 transporter and that is why, when porin is deleted, the drug resistant phenotype 
is no longer seen.  
 










Our experiments suggest that Porin plays a role in the control of Pdr5 level and activity. To 
investigate this further we introduced a Porin1 expression plasmid into wild-type, cof1-6 
and associated porin deletions. We also transformed an empty vector into the strains as a 
control. To confirm the porin overexpression, a western blot was done using a porin specific 
mouse antibody (Figure 3.15). The resulting western blot showed elevated levels in all of 
Figure 3.15 Western blot to confirm the overexpression of porin. The first probe is with a porin specific mouse 
antibody, whereas the second probe is the actin loading control. Lanes 1-4 contain the empty vector control strains, 
and lanes 5-8 contain the porin overexpression strains. Porin overexpression is clearly seen in lanes 4-8 in relation 
to lanes 5-8. 
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the plasmid inserted clones. It is important to note that Por1 levels were significantly higher 
than observed in the empty vector control strains (Figure 3.15). Having confirmed Porin 
overexpression we investigated its effect upon resistance we performed a spotting assay 







Deletion of porin leads to sensitivity to all drugs tested in a wild type background while 
Expression of cof1-6 control demonstrated resistance to Itraconazole as before. Deletion 
of porin prevented resistance to itraconazole while porin overexpression reduced 
resistance in all cases. The overexpression of Porin also led to a reduction in resistance to 
amphotericin B in all strains.  These results suggest that porin level and/or its function is 
Figure 3.16 Spotting assay showing the effect of porin overexpression on drug resistance.  Overnight cultures of 
strains were diluted to a starting OD600 of 0.1, and serially diluted 1 in 10. They were then grown in the presence of 
itraconazole at 4.4µM and amphotericin B at 0.6µg/ml. The plates were left to grow for 2 days at 30oC.  Porin 
overexpression does not affect resistance to Itraconazole but increases sensitivity to Amphotericin B.  
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important in drug resistance. One possibility is that porin plays a role in the control of lipid 
maturation within the mitochondria and that this leads to changes in transporter activity 
or localisation or to the lipid composition of the cell.  
 
3.8 Investigating lipid organisation cof1-6 and porin mutant cells 
Our data suggests that cofilin and porin may function to influence the lipid environment of 
the cell and that this in turn may influence drug resistance. Mutations in the cof1-6 strain 
have been seen to result in the upregulation of fatty acid beta-oxidation in cells. In addition, 
mitochondria are involved in the maturation of phosphatidylserine to 
phosphatidylethanolamine. To investigate lipid organisation, we made use of GFP labelled 
probes that recognise specific phospholipids using fluorescence microscopy. Using these 
probes, we investigated phosphatidylinositol 4-phosphate (PI4P) and phosphatidylinositol 
3-phosphate (PI3P) localisation in the wild-type, cof1-6 and corresponding porin deletions. 
PI3P is a phospholipid that is located in the plasma membrane and is responsible for 
recruiting protein trafficking proteins to the membrane (Gillooly et al, 2000). PI4P is a 
phospholipid located in the Golgi apparatus which has a role in the recruitment of proteins 
that are destined for the cell membrane (Stefan et al, 2011). Overnight cultures of the 
strains were inoculated for four hours and visualised in early log phase, or inoculated for 
























Figure 3.17 GFP localisation phenotypes observed in the GFP-tagged PI3P strains. The cells were inoculated 
from an overnight culture and grown to stationary phase for 24 hours. The images were analysed in ImageJ. The 
cells either showed a number of different phenotypes like localisation to the cell membrane (A), localisation to 
the membrane but also with a single foci (B), localisation with multiple foci (C), a single foci with no membrane 
localisation (D), or a diffuse signal (E).  Bar chart shows the average number of each phenotype in each strain. At 
least 180 cells were counted in total for each strain, with at least 4 technical repeats. * corresponds to a P value = 
<0.05, ** corresponds to a P value = <0.01, *** corresponds to a P value <0.001. 















PI3P could be observed at a number of different locations in the wild-type and mutant 
strains. The wild-type had predominantly GFP localisation at the plasma membrane with a 
multiple foci also at the plasma membrane. They also displayed a large percentage of cells 
with membrane localisation but no foci (Figure 3.17, C). The ȴƉŽƌ ? showed a similar 
phenotype to the wild-type showing no significant difference in single foci (P value = 
0.0797) or multiple foci (P value = 0.3553). The cof1-6 had a similar percentage of cells with 
membrane only localisation to the ȴƉŽƌ ? strain but less multiple foci with membrane 
localisation than the wild-type (P value = 0.039). The cof1-6 ȴƉŽƌ ? had the most distinct 
phenotype of all, with almost all GFP-expressing cells showing a diffuse signal, a phenotype 
that was also seen in the ȴƉŽƌ ? but only in 1% (Figure 3.17). Some cof1-6 ȴƉŽƌ ? displayed 
single foci but no membrane localisation (Figure 3.17, D). This suggest that porin is 




















Figure 3.18 GFP localisation phenotypes observed in the GFP-tagged PI4P strains. The cells were inoculated from 
an overnight culture and grown to stationary phase for 24 hours. The images were analysed in ImageJ. The cells 
either showed a number of different phenotypes like a single localised foci (A), multiple localised foci (B), 
localisation to a single foci elongated along a membrane (C), localisation to an internal circular membrane (D), or a 
diffuse signal (E). Bar chart shows the average number of each phenotype in each strain. At least 550 cells over 3 
technical repeats were counted from each strain. * corresponds to a P value = <0.05, ** corresponds to a P value = 
<0.01, *** corresponds to a P value <0.001. 
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The most common localisation phenotype observed with the GFP PI4P probe was a single 
localised foci, most likely at the Golgi apparatus as documented, although some cells also 
displayed multiple localised foci (Figure 3.18). The ȴƉŽƌ ? showed a similar phenotype 
compared to the wild-type with most of cells showing a single localised foci (P value = 
0.3304) or multiple foci (P value = 0.1741). The cof1-6 strain showed a lot less single foci (P 
value = < 0.0001) and more multiple foci compared to the wild type (P value = 0.0231) 
(Figure 3.18). The cof1-6 cells mostly showed either no signal, elongated foci or localisation 
to an internal circular membrane. The cof1-6 was the only strain that showed localisation 
to an internal circular membrane. The cof1-6 ȴƉŽƌ ? cells mostly had a diffuse signal (Figure 
3.18, E), a phenotype not seen in the other strains. These results may indicate that that 
there is mis-localisation of PI4P in the cof1-6 strain, but without porin there localisation is 











In order to determine whether the  foci seen in the cof1-6 strains in the PI3P and PI4P were 
associated with the vacuole we made use of the stain  FM6-64. The resulting images are 
seen in Figure 3.19. In the PI3P stained wild-type strain, the signal was localised to the cell 
embrane as expected, with the foci localised at points along that membrane. In the wild-
type the vacuole was intact and usually observed as a single entitiy. In contrast the  vacuole 
in  cof1-6 cells appeared to be fragmented, with the GFP signal at the membrane with the 
foci dotted along it. The cof1-6 ȴƉŽƌ ? strain showed a difuse signal throughout the entire 
cell with a vacuole similar to the wild-type cells. In the PI4P microscopy the signal localised 
Figure 3.19 Staining of the vacuole and PI3P and PI4P sensors showed fragmented vacuoles and mis-localisation 
of GFP signal in the cof1-6 strain.  The strains were transformed with GFP-tagged PI3P and PI4P sensors, as well as 
being stained with FM4-64, a vacuole stain. The cof1-6 strain shows both fragmented vacuoles and mis-localisation 




to the vacuole with single foci in most cells that presented the GFP tagged PI4P. The cof1-
6 showed foci within the often fragemented vacuole with some localised at the inner 
vacuole membrane. In the cof1-6 ȴƉŽƌ ?, as seen in the PI3P localisation, had a diffuse signal 
throught the cell with a normal looking vacuole the same as the wild-type. These data 
































The actin cytoskeleton is a dynamic structure which is capable of rapid assembly and 
disassembly, and has roles in many cell processes. Previous research has linked the actin 
regulatory protein Cofilin to drug resistance in yeast. There has also been links between 
cofilin and drug resistance in cancer, although the exact mechanisms of resistance are yet 
to be determined. Phosphorylation of cofilin has been linked to HDAC resistance in 
hepatocellular carcinoma, and cofilin has also been associated with apelin-13 regulated cell 
migration in adenocarcinoma(Liao et al, 2016; Lv et al, 2016). Cofilin, encoded by the COF1 
gene, acts to depolymerises F-actin. We studied a mutation in cofilin, cof1-6, that elevates 
mitochondrial function and activates a robust drug resistance phenotype.  
Here we show that cof1-6 mutant cells express high levels of the ABC transporter Pdr5 in a 
manner that is dependent upon the mitochondrial membrane protein Porin. We 
hypothesise that cofilin mutation leads to overexpression of Pdr5 and that porin is essential 
for its activation. Our data suggests that mitochondria participate in drug resistance via 
their role in lipid organisation.  
 
4.1 Evidence for the presence of an adaptive drug resistance response to cell wall or 
plasma membrane damage by antifungal agents 
The mechanisms by which yeast cells elicit a multi-drug resistance response are unclear. 
One possibility is that chemical damage at the level of the cell wall or plasma membrane is 
linked to a multi-drug resistance response. We entertained the possibility that cofilin may 
play a role in sensing cell wall or cell membrane stress, given its known affinity for 
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phospholipids, and that changes in its binding to lipids in the plasma membrane may 
mediate an adaptive drug resistance response. As an extension of this hypothesis we 
postulated that the change from positively charged lysine to alanine in cof1-6 leads to 
changes in plasma membrane association that in turn activate a drug resistance response.   
Our original hypothesis was that drug resistance was response to cell wall stress in the cof1-
6 mutant, and this was induced through the PKC/MAPK CWI pathway. However, treatment 
of cof1-6 cells with Cercosporamide, an inhibitor of PKC, did not affect in drug resistance 
associated with cof1-6. This might indicate that Pkc1 activation is not involved in cofilin 
mediated drug resistance. and that the CWI pathway is not the trigger for drug resistance 
within the cof1-6 mutant. In agreement with this we saw no activation of Slt2, the terminal 
MAPK activated by Pkc1 signalling within the CWI pathway.  
 
4.2 Rsb1 expression dependant on expression of Porin 
Interestingly in the cof1-6 mutant the expression of the lipid transporter Rsb1 are 
increased. As Rsb1 is involved in the regulation of lipid within the plasma membrane bilayer 
we hypothesised that the cof1-6 mutation mimicked a membrane stress response that also 
led to the upregulation of a number of plasma membrane transporters that could influence 
drug resistance, such as Pdr5. In fact, Pdr5 is known to act both as a drug pump and a lipid 
transporter (Mahé et al, 1996). We investigated if lipid stress may influence Rsb1 levels 
and/or multi-drug resistance. However, treatment with the sphingolipid precursor 
ceramide, which is lethal to S. cerevisiae in high doses, also had no effect upon drug 
resistance in strains investigated. Rsb1 expression is upregulated by the RIM101 pathway 
which in turn is activated in response to changes in cell surface charge(Ikeda et al, 2008). 
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Ikeda et al hypothesised that changes in the lipid asymmetry could be detected by the 
RIM21 sensors, part of the RIM101 pathway thus activating RSB1. These changes in lipid 
asymmetry could result in negatively charged phospholipids such as PS and PI being 
exposed on the cell surface, and this negative charge being subsequently detected by 
RIM21. However, we did not observe changes in Rsb1 promoter activity in response to 
alkaline conditions. 
As the cof1-6 has shown dysregulation of the cell membrane, the elevated Rsb1 expression 
could be explained by these changes in membrane asymmetry, with PS and PI being 
exposed and detected by the RIM101 pathway. Interestingly deletion of the mitochondrial 
outer membrane protein porin prevented the increase in Rsb1 promoter activity observed 
in cof1-6 cells. One possibility is that porin is involved in the formation of ERMES junctions. 
ERMES junctions are mitochondria/ER interaction channels which have many important 
physiological functions within the cell. The primary function of these channels is to allow 
the transfer of phospholipids from the ER to the mitochondria. The majority of 
phospholipids are made in the Endoplasmic Reticulum but as mitochondria are not part of 
the endomembrane system, they cannot receive phospholipids required for their inner and 
outer membranes through vesicular trafficking. One purpose of these ERMES junctions is 
to allow an alternative route by which mitochondria can receive these phospholipids it 
requires (Michel & Kornmann, 2012).  
The mitochondria is also a crucial element in the post translational modification of 
important lipids required at the cell wall. The ERMES junction allows a contact point where 
lipids can enter the mitochondria to undergo decarboxylation. The mitochondria is the site 
where phosphatidylserine (PS) is decarboxylated to phosphatidylethanolamine (PE) by the 
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enzyme phosphatidylserine decarboxylase 1 (Psd1). Psd1 is an enzyme that is located in the 
mitochondria so the precursor, PS, must cross from the ER to the mitochondria, be 
converted to PE before crossing back to the ER again (Michel & Kornmann, 2012). In the ER 
PE is converted to phosphatidylcholine which is the most prevalent phospholipid found in 
the membranes of yeast cells (Choi et al, 2004).   
 We hypothesise that removing porin, and so damaging ERMEs connections to the ER, could 
result in less PS being transported to the plasma membrane which could in turn lead to the 
activation of the RIM101 pathway and Rsb1. Alternatively, it could be that direct and as yet 
undescribed signalling mechanisms are controlled by Porin leading to changes in Rsb1 
expression. 
 
4.3 Deletion of PDR5 increases resistance to Amphotericin B and Flucytosine 
Interestingly we saw a gain in resistance to Amphotericin B and Flucytosine in the PDR5 
deletion strains which is similar to results seen in a paper by Guan et al. in which they saw 
also saw a gain of resistance to Amphotericin after deleting PDR5 in S. cerevisiae. Guan et 
al. hypothesised that Pdr5 was involved in the synthesis of ergosterol, the target of 
Amphotericin B, and when PDR5 was deleted, ergosterol levels were reduced resulting in 
the resistance seen. 
Research by Kotiadis et al. showed that although levels of ergosterol were reduced in the 
cof1-6 mutant in log phase, the levels did not vary between the mutant and wild-type in 
stationary, concluding that there was no difference in ergosterol synthesis(Kotiadis et al, 
2012). However, no such analysis of ergosterol synthesis in the cof1-6 ȴpdr5 mutant has 
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been done. Although no other papers linking Pdr5 to ergosterol synthesis have emerged, 
this hypothesis would also explain the gain in resistance to amphotericin seen in the wild-
type ȴpdr5 mutant.   
Other explanations for a gain in amphotericin could include mutations in ERG6, a gene 
involved in ergosterol biosynthesis which have been shown to bestow resistance to 
polyenes to mutants (Vandeputte et al, 2008). This could make sense for the cof1-6 ȴpdr5 
ŵƵƚĂŶƚďƵƚĐŽƵůĚŶ ?ƚĞǆƉůĂŝŶƚŚĞŝŶĐƌĞĂƐĞŝŶƌĞƐŝƐƚĂŶĐĞŽƌŐĂŝŶŽĨƌĞƐŝƐƚĂŶĐĞŝŶƚŚĞǁŝůĚƚǇƉĞ
ȴpdr5 unless there PDR5 and ERG6 were linked, however Emter et al. showed that drug 
resistance via ERG6 and PDR5 occur through different distinct pathways(Emter et al, 2002). 
Another possibility could be that the deletion of PDR5 results in the upregulation of other 
drug pumps which are able to remove Amphotericin and Flucytosine. Other transporters 
seen to be upregulated in the cof1-6 mutant were Pdr15 and Pdr10. Deleting PDR10 has 
been seen to have no effect on amphotericin resistance, however Pdr15 has been seen to 
show similar properties to Pdr5(Rockwell et al, 2009)(Schüller et al, 2007). It could be 
possible that deleting PDR5 induces increased Pdr15 expression to compensate for the loss 
of the most prevalent transporter. 
 
 
4.4 Deletion of PDR5 results increased rate of growth 
Deleting PDR5 in both the cof1-6 mutant and the wild-type background resulted in an 
increased growth rate and final density when compared to the wild-type and cof1-6 strains. 
This suggests that the production of Pdr5 within the cell requires large amounts of energy 
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expenditure that could be focused into growth, and when PDR5 is deleted, it allows the 
redirection of this energy. Alternatively, Pdr5 could be involved in the control of cell cycle 
or response to quorum sensing mechanisms that limit cell number. This would require 
further research as Pdr5 has not previously been linked to growth regulation.  
 
4.5 Porin and cofilin work in separate pathways to control Pdr5 levels 
As well as in the cof1-6, Pdr5 upregulation was seen in both the ȴƉŽƌ ? and cof1-6 ȴƉŽƌ ? 
strains. Deleting porin in the wild-type induced Pdr5 expression to similar levels as seen in 
the cof1-6 mutant. Furthermore, the cof1-6 ȴƉŽƌ ? showed more expression than the cof1-
6, indicating that this Pdr5 expression seen by deleting porin is cumulative. This result 
suggests that the regulation of Pdr5 levels is controlled independently by cofilin and porin 
via two distinct mechanisms. At this point both pathways are uncharacterised. Further 
evidence for a role for Porin in the control of drug resistance was observed upon its over-
expression. The over-expression of porin in the cof1-6 mutant, made it more sensitive to 
all of the drugs at the concentrations tested.  
 
4.6 Porin possibly required for ERMES Junction formation 
We hypothesis that porin plays a role in lipid regulation and that this is linked to a role in 
drug resistance. One possibility is that loss, or overexpression of Porin changes 
mitochondrial/ER contacts at ERMES junctions that in turn affects the localisation of plasma 
membrane transporters such as Pdr5.  Interestingly our data suggest changes in PI3P and 
PI4P localisation, especially in the absence of porin, in the cof1-6 strain, with a diffuse signal 
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throughout the cell. This could indicate the role of porin in the regulation of lipid 
organisation within the cell. One possibility is that this could occur via lipid maturation at 
ERMES junctions. Interestingly Psd1 has been seen to have a role in mediating Pdr5 
expression (Gulshan et al, 2008). Gulshan et al. showed that the overexpression of Psd1 
resulted in the expression of Pdr5 dependant of Pdr3. They also showed that deleting PSD1 
prevented Pdr5 expression. Finally, they showed that even when Psd1 was inactive and 
unable to form PE, Pdr5 levels were increased, showing that PE levels were not the 
mediating factor in drug resistance. 
It has been shown that in mammalian cells, the oxysterol-binding protein (OSBP)-related 
protein 5 (ORP5) and ORP8 are involved in delivering PS from the ER to the plasma 
membrane where it is then exchanged for PI4P. This PI4P is delivered to the ER and 
exchanged for PS. The PI4P is then localised to the PI4P phosphatase Sac1 where it is 
degraded(Chung et al, 2015)(Galmes et al, 2016). In yeast cells this process has been seen 
to be conserved, with the ORP homologues Osh proteins, Osh6 and Osh7 
respectively(Stefan et al, 2011)(Chung et al, 2015). The mis-localisation of PI4P in the cof1-
6 ȴƉŽƌ ? cells could show a problem with PI4P/PS transport linked to PS synthesis. 
It is possible that porin has a role in the formation of these ERMES junctions, so when it is 
deleted in the cof1-6 background, these junctions cannot be formed, resulting in the cell 
unable to make PC. This would explain the mis-localisation of the PI4P signal in the cof1-6 
ȴƉŽƌ ? mutant. Porin may also interact with Psd1 resulting in overexpression. Further study 




4.7 Cofilin and Porin act to control Pdr5 levels and its localisation to the plasma 
membrane 
In light of our findings we propose a model by which cofilin and porin act together to 
regulate drug resistance. Cofilin has been previously seen to upregulate ABC transporters 
seen in drug resistance, including Pdr5, through interaction with the mitochondria. We 
hypothesise that changes in the membrane charge such results changes cofilin/membrane 
interaction that signals the nucleus to activate the transcription factor Pdr1 which controls 
the expression of a battery of plasma membrane transporters. We speculate that porin has 
a role in the organisation of the lipid membrane, potentially through the formation of 
ERMES junctions, and as such, is involved in the localisation of Pdr5. In the absence of porin, 
this localisation of Pdr5 cannot occur and remains in some sort of lipid compartment. As a 
result, whilst there is high levels in the cof1-6 mutant ȴƉŽƌ ? deletion, it does not express 






4.8 Future Work 
x Due to time restraints, we were not able to determine the localisation of the Pdr5 
within the mutant strains. A GFP-tagged Pdr5 construct has been transformed into 
the wild-type, cof1-6 and the porin deletions for use in microscopy which will be 
done in the future. Our hypothesis is that in cof1-6 ȴƉŽƌ ? strain, the Pdr5 will not 
be localised to the cell wall whereas in the wild-type and cof1-6 strains, the Pdr5 
should be targeted at this membrane. If this hypothesis proves correct, further work 
will be required to determine the compartment that Pdr5 is contained in. 
Figure 4.1 Model showing the proposed involvement of Porin and Cofilin in Pdr5 expression. We propose that 
Pdr5 localisation to the lipid membrane is dependent on Porin. In the absence of Porin, Pdr5 remains contained in 
an unknown lipid compartment and therefore in an inactivated state.  
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x To determine the involvement of ERMES junctions, knockout the genes MDM10, 
MDM34, MMM1, GEM1 in the cof1-6 background to see if the same phenotype is 
observed as seen in the cof1-6 ȴƉŽƌ ? strain. These genes are subunits of the ERMES 
complex so if porin is responsible for the formation, deleting them should remove 
the resistant phenotype seen, in the same way it is removed in the cof1-6 ȴƉŽƌ ? 
strain. 
x Levels of Psd1 within the mutant cof1-6 needs to be determined as does its 
localisation within the mutant cell. 
x Deletion of other pleiotropic drug resistance genes upregulated in the cof1-6 
mutant as seen in the paper by Kotiadis et al. 
x Characterisation of all lipid concentrations at the plasma membrane needs to be 
done to see if the levels of PS, PE and PC vary in the cof1-6 mutant in comparison 
to the wild-type. 
x The porin overexpression strains should be tested by western blot to see how 
elevated porin effects the expression Pdr5. We hypothesise that the levels of Pdr5 
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